CHI & MassBio to Co-Host Congressional Briefing on Infectious Disease Research and Therapeutic Advancements, Innovations a

--(BUSINESS WIRE)-- CHI-California Healthcare Institute:

WHAT:

 

CHI-California Healthcare Institute and MassBio will host a congressional briefing to highlight biomedical research and innovation in technologies to detect, diagnose, prevent and treat infection, such as healthcare-associated infections and antibiotic-resistant infections. This program will include an overview of advances stemming from California’s and Massachusetts’ life sciences sectors, with an expert panel discussing current statistics and drug, device and diagnostics development.

 

WHEN:

Wednesday, October 12, 9 a.m. to 11 a.m.

 

WHERE:

Rayburn House Office Building 2168, Gold Room, Washington, D.C., 20515

 

WHO:

Reps. Jackie Speier (D-Calif.) and Ed Markey (D-Mass.) will provide welcome remarks. The event will feature several health experts including: David L. Gollaher, Ph.D., CHI President and CEO; Robert Coughlin, MassBio President and CEO; Cubist Pharmaceuticals Vice President, Chief IP Counsel Tim Douros, J.D.; CareFusion Vice President for Clinical Research Dr. Richard Johannes; Thermo Fisher Scientific Director of Business Development and Commercial Operations, Clinical Diagnostics Division, Arnold Huang, Ph.D; BD Vice President of Infection Prevention Kathy Warye; and Theravance CEO Rick Winningham.

 

WHY:

Healthcare-associated infections (HAIs) are the most common complication of hospital care and are the 10th leading cause of death in the United States, accounting for 2 million infections, nearly 100,000 deaths per year, and $3.1 billion in excess healthcare costs. According to the California Department of Public Health, approximately 12,000 people die in the state each year of HAIs. As reported by the Massachusetts Department of Public Health, an estimated 34,000 HAIs render a financial burden of almost $400 million annually. Additionally, antibiotic resistance can also cause an economic burden on the healthcare system. According to the Centers for Disease Control and Prevention (CDC), antibiotic resistant infections cost more to treat and can prolong healthcare use. In the U.S., antibiotic-resistant infections are responsible for $20 billion in excess healthcare costs, $35 billion in societal costs and $8 million in additional hospital days. CHI and HINJ members BD, CareFusion, Cepheid, Cubist, Theravance and Thermo Fisher Scientific are all working to advance important new diagnostics and therapeutics.

 

RSVP:

Caitlin Doyle, CHI’s associate director of federal government relations and programs ([email protected] or 202-974-6323).

 

ABOUT CHI:

CHI represents more than 275 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.

 

ABOUT MassBio:

The Massachusetts Biotechnology Council (MassBio), a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and health care, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services. Visit www.massbio.org.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50017920&lang=en



CONTACT:

CHI-California Healthcare Institute
Nicole Beckstrand, 858-456-8881
[email protected]
or
MassBio
Sarah MacDonald, 617-674-5115
[email protected]

KEYWORDS:   United States  North America  District of Columbia  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Public Policy/Government  Congressional News/Views  Public Policy

MEDIA:

Logo
 Logo

Suggested Articles

Biogen will develop a gene therapy with the goal of preserving and possibly restoring vision in patients with PRPF31-mutated retinitis pigmentosa.

A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is testing the drug's ability to ward off COVID-19 infection.

Short reports are nothing new, but the aggressive “I’m coming after you” PR from Applied Therapeutics certainly is.